These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 21903767)
1. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Valerie NC; Casarez EV; Dasilva JO; Dunlap-Brown ME; Parsons SJ; Amorino GP; Dziegielewski J Cancer Res; 2011 Nov; 71(21):6817-26. PubMed ID: 21903767 [TBL] [Abstract][Full Text] [Related]
2. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Woynarowska BA; Roberts K; Woynarowski JM; MacDonald JR; Herman TS Radiat Res; 2000 Oct; 154(4):429-38. PubMed ID: 11023607 [TBL] [Abstract][Full Text] [Related]
3. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384 [TBL] [Abstract][Full Text] [Related]
4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513 [TBL] [Abstract][Full Text] [Related]
5. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Moretti L; Niermann K; Schleicher S; Giacalone NJ; Varki V; Kim KW; Kopsombut P; Jung DK; Lu B Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1189-97. PubMed ID: 21514073 [TBL] [Abstract][Full Text] [Related]
6. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression. Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044 [TBL] [Abstract][Full Text] [Related]
7. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Cuellar DC; Rhee J; Kyprianou N Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Iwase K; Evers BM; Hellmich MR; Kim HJ; Higashide S; Gully D; Thompson JC; Townsend CM Cancer; 1997 May; 79(9):1787-93. PubMed ID: 9128997 [TBL] [Abstract][Full Text] [Related]
9. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Hagan M; Yacoub A; Dent P Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899 [TBL] [Abstract][Full Text] [Related]
10. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741 [TBL] [Abstract][Full Text] [Related]
11. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998 [TBL] [Abstract][Full Text] [Related]
12. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142 [No Abstract] [Full Text] [Related]
13. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells. Zhang Y; Zhu S; Yi L; Liu Y; Cui H Mol Cell Biochem; 2014 Apr; 389(1-2):1-8. PubMed ID: 24357116 [TBL] [Abstract][Full Text] [Related]
14. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597 [TBL] [Abstract][Full Text] [Related]
15. PAFR selectively mediates radioresistance and irradiation-induced autophagy suppression in prostate cancer cells. Yao B; Liu B; Shi L; Li X; Ren C; Cai M; Wang W; Li J; Sun Y; Wu Y; Wen J Oncotarget; 2017 Feb; 8(8):13846-13854. PubMed ID: 28099922 [TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor-induced cell death and radiosensitization in epidermal growth factor receptor-overexpressing cancer cell lines. Kim K; Wu HG; Jeon SR Anticancer Res; 2015 Jan; 35(1):245-53. PubMed ID: 25550557 [TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802 [TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Dai Y; Liu M; Tang W; DeSano J; Burstein E; Davis M; Pienta K; Lawrence T; Xu L Clin Cancer Res; 2008 Dec; 14(23):7701-10. PubMed ID: 19047096 [TBL] [Abstract][Full Text] [Related]
19. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. Ni X; Zhang Y; Ribas J; Chowdhury WH; Castanares M; Zhang Z; Laiho M; DeWeese TL; Lupold SE J Clin Invest; 2011 Jun; 121(6):2383-90. PubMed ID: 21555850 [TBL] [Abstract][Full Text] [Related]
20. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer. Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]